[Do diabetologists choose a  therapy rationally? Basic results of the PROROK project (A prospective observation project to assess the relevance of the difference between fasting glycemia and postprandial glycemia to estimation of success of type 2  XXXX therapy)].

@entity1 @entity6 @entity28 @entity1674 @entity8142
INTRODUCTION: The PROROK project (A prospective observation project to assess the relevance of the difference between fasting glycemia and postprandial glycemia to estimation of success of type 2 @entity6 therapy) had a character of a non-interventional, prospective, multicentric observation project conducted for a period of 6 months, whose aim was to quantify the relevance of the difference between fasting and postprandial glycemia to the success of @entity8142 agonist treatment, or insulin therapy with basal or premixed insulin, or a combination of basal and bolus insulin. Physicians chose therapy for inadequately compensated @entity1 at their own discretion, with 4   972 @entity1 included. AIM: The study aimed at the assessment of the differences in basic anthropometric and biochemical parameters between the @entity1 cohorts included in the PROROK project with regard to the therapy selected by the treating diabetologist. METHODOLOGY AND RESULTS: The @entity1 treated with @entity8142 agonists were quite young, they have suffered from @entity6 for a shorter period of time and at the same time were more @entity28 and had the highest concentration of @entity1674 . The @entity1 who underwent basal insulin therapy, had the highest fasting glycemia. The @entity1 for whom premixed insulin therapy or basal/bolus insulin regimen were chosen, manifested the highest postprandial glycemia, those with basal/bolus insulin regimen had the highest initial glycated haemoglobin. The difference between fasting and postprandial glycemia was the smallest in the cohort for which basal insulin therapy was chosen and the greatest in the cohort chosen for the therapy with premixed insulin, or with the basal/bolus insulin combination. Average improvement in glycated haemoglobin values reached 1.6 % within the whole cohort, a median of the resulting glycated haemoglobin reached 5.9 % or 5.8 % ( @entity8142 agonist treatment). All the differences amounted to p < 0.001. CONCLUSION: Bearing in mind that the differences established in the parameters describing the cohorts, although statistically relevant, are of smaller clinical relevance, we regard as an important finding that the choice of therapy is in accordance with the basic knowledge about the pathophysiology of type 2 @entity6 and possibilities of an individually chosen targeted intervention with antidiabetic therapy. We may conclude that most of the physicians participating in the PROROK project choose their therapy in a rational manner.Key words: @entity8142 agonists - basal insulin - intensified insulin regimen - insulin - premixed insulin - type 2 @entity6 therapy.
